Global API Contract Manufacturing Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global API Contract Manufacturing Market Research Report 2024
Contract manufacturing is the process where manufacturer engages into an agreement with the companies for component or product manufacturing. Active pharmaceutical ingredient (API) contract manufacturing refers to the development of pharmaceutical drugs through contract manufacturing by outsourcing to other companies.
According to Mr Accuracy reports’s new survey, global API Contract Manufacturing market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole API Contract Manufacturing market research.
Key companies engaged in the API Contract Manufacturing industry include AstraZeneca Plc, BoehringerIngelhein GmbH, GlaxoSmithKline Pharmaceuticals Ltd, Merck&Co.,Inc, Novartis AG, Piramal Pharma Solutions, Ranbaxy Laboratories Ltd., Reddy's Laboratories Ltd and Sandoz-Lek-Biochemie, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of API Contract Manufacturing were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole API Contract Manufacturing market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global API Contract Manufacturing market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca Plc
BoehringerIngelhein GmbH
GlaxoSmithKline Pharmaceuticals Ltd
Merck&Co.,Inc
Novartis AG
Piramal Pharma Solutions
Ranbaxy Laboratories Ltd.
Reddy's Laboratories Ltd
Sandoz-Lek-Biochemie
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals Industries Ltd
Segment by Type
Commercial Manufacturing
Clinical Manufacturing
Oncology
Central nervous system
Cardiovascular disorder
Infectious diseases
Pulmonary disorders
Metabolic disorder
Gastrointestinal disorders
Musculoskeletal disorders
Genitourinary disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The API Contract Manufacturing report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global API Contract Manufacturing market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole API Contract Manufacturing market research.
Key companies engaged in the API Contract Manufacturing industry include AstraZeneca Plc, BoehringerIngelhein GmbH, GlaxoSmithKline Pharmaceuticals Ltd, Merck&Co.,Inc, Novartis AG, Piramal Pharma Solutions, Ranbaxy Laboratories Ltd., Reddy's Laboratories Ltd and Sandoz-Lek-Biochemie, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of API Contract Manufacturing were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole API Contract Manufacturing market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global API Contract Manufacturing market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca Plc
BoehringerIngelhein GmbH
GlaxoSmithKline Pharmaceuticals Ltd
Merck&Co.,Inc
Novartis AG
Piramal Pharma Solutions
Ranbaxy Laboratories Ltd.
Reddy's Laboratories Ltd
Sandoz-Lek-Biochemie
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals Industries Ltd
Segment by Type
Commercial Manufacturing
Clinical Manufacturing
Segment by Application
Oncology
Central nervous system
Cardiovascular disorder
Infectious diseases
Pulmonary disorders
Metabolic disorder
Gastrointestinal disorders
Musculoskeletal disorders
Genitourinary disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The API Contract Manufacturing report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source